Please login to the form below

Not currently logged in

Burson-Marsteller appoint new EMEA health MD

Kate Hawker joins the agency from InforMed

Burson-Marsteller, Kate Hawker

Burson-Marsteller has appointed Kate Hawker as the new MD and chair of its EMEA and UK healthcare divisions.

“Kate is an excellent, and welcome, addition to Burson-Marsteller's outstanding group of EMEA practice chairs,” said Jeremy Galbraith, CEO of Burson-Marsteller EMEA.

“She brings the healthcare expertise and individual creativity that clients justifiably expect from a leading global agency and I am delighted she is joining us.”

She joins the agency after three years as business development director for InforMed, following the acquisition of her start-up medical communications company Medea.

During her 25-year career Hawker has directed pan-European and UK medical communications and PR programmes, having worked on campaigns for GSK, Baxter, Takeda, Boehringer-Ingelheim, Bristol Meyer Squibb, MSD and others.

She has also been a director and partner at Fleishman-Hillard, director at OCC and associate director for Shire Health International.

Commenting on her appointment, Hawker said: “I'm delighted to be joining Burson-Marsteller, an agency with a stand-out reputation for delivering integrated communications campaigns on a UK, EMEA and global level. I'm looking forward to working with a great team both in the UK and across EMEA.”

20th November 2012

From: Marketing, Healthcare



Featured jobs

Subscribe to our email news alerts


Add my company

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...